A New Class of Immunotherapies Selecta is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease. Our proprietary technology platform of Synthetic Vaccine Particles (SVP™) is a product engine for the durable and antigen-specific treatment of undesired immune responses. Our antigen-specific, tolerogenic SVPs can be applied in a variety of therapeutic areas with large unmet medical need, and we are strategically focused on three key applications: inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases. Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, we are building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases. Learn More News Profile September 8, 2015 - Selecta Announces $38 Million Series E Financing Read More September 8, 2015 - Selecta Appoints Earl E. Sands, MD, as Chief Medical Officer Read More June 18, 2015 – Selecta Biosciences’ Synthetic Vaccine Particles Instrumental in Breakthrough Research on Mucosal Vaccines Read More June 10, 2015 – Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout Read More May 13, 2015 – Genethon and Selecta Collaborate to Create Next Generation Gene Therapies Using Selecta's Synthetic Vaccine Particle Platform Read More May 13, 2015 – Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology Read More Careers QC, Research Associate Read More © 2015 Selecta Biosciences, Inc. | 480 Arsenal St., Building One, Watertown, MA 02472 | Phone: 617-923-1400 | Fax: 617-924-3454 | Email: info@selectabio.com Privacy Policy | Web site designed and developed by RainCastle Communications, Inc.